Evaluation of Cytochrome P450 3A4-Mediated Drug–Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation

A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4

(2016) Ian Templeton et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

(2015) Kelong Han et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug–drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling

(2015) Jia Chen et al.   Expert Opinion on Drug Metabolism & Toxicology

Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies

(2014) A B Ke et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of Genetic Polymorphism on Drug-Drug Interactions Mediated by Cytochromes: A General Approach

(2013) Michel Tod et al.   AAPS Journal

Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data

(2013) Anna Nordmark et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Absolute Bioavailability and Effect of Formulation Change, Food, or Elevated pH with Rabeprazole on Cobimetinib Absorption in Healthy Subjects

(2013) Luna Musib et al.   MOLECULAR PHARMACEUTICS

Mechanistic Understanding of the Effect of PPIs and Acidic Carbonated Beverages on the Oral Absorption of Itraconazole Based on Absorption Modeling with Appropriate in Vitro Data

(2013) Nikoletta Fotaki et al.   MOLECULAR PHARMACEUTICS

Physiologically based pharmacokinetic (PBPK) modeling: It is here to stay!

(2012) Amin Rostami-Hodjegan et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

(2012) Kenneth D. Rice et al.   ACS Medicinal Chemistry Letters

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype

(2010) Dinko Rekić et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review

(2010) P Zhao et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS